Patients in the NHS Cancer Vaccine Launch Pad trials will have vaccines tailored to their DNA using mRNA technology, with 30 sites across the UK offering enrollment.
NHS's program collaborates with BioNTech, known for mRNA COVID-19 vaccines, to customize cancer treatments and potentially detect colorectal cancer early via circulating tumor DNA.
National matchmaking service will ensure eligible patients can join trials; the NHS aims to cover diverse cancer types as the program progresses beyond six initial types.
[
Collection
]
[
|
...
]